{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:28:30Z","timestamp":1789579710459,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40261-019-00853-x","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:50:18Z","timestamp":1569891018000},"page":"1141-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use"],"prefix":"10.1007","volume":"39","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"853_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","volume":"308","author":"J Doolittle","year":"2016","unstructured":"Doolittle J, Walker P, Mills T, et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743\u20139.","journal-title":"Arch Dermatol Res."},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21037\/shc.2019.05.05","volume":"3","author":"EN Hasimoto","year":"2019","unstructured":"Hasimoto EN, Cataneo DC, dos Reis TA, et al. Hyperhidrosis prevalence and its impact on population. Shanghai Chest. 2019;3:30.","journal-title":"Shanghai Chest."},{"issue":"11","key":"853_CR3","first-page":"729","volume":"97","author":"JR McConaghy","year":"2018","unstructured":"McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician. 2018;97(11):729\u201334.","journal-title":"Am Fam Physician."},{"issue":"4","key":"853_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaad.2010.03.013","volume":"64","author":"HW Walling","year":"2011","unstructured":"Walling HW. Clinical differentiation of primary from secondary hyperhidrosis. J Am Acad Dermatol. 2011;64(4):690\u20135.","journal-title":"J Am Acad Dermatol."},{"key":"853_CR5","first-page":"S496","volume":"24","author":"CI Jacob","year":"2018","unstructured":"Jacob CI. Examining hyperhydrosis: an update on new treatments. Am J Manag Care. 2018;24:S496\u2013501.","journal-title":"Am J Manag Care."},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12955-017-0693-x","volume":"15","author":"P Kamudoni","year":"2017","unstructured":"Kamudoni P, Mueller B, Halford J, et al. The impact of hyperhidrosis on patients\u2019 daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15:121.","journal-title":"Health Qual Life Outcomes."},{"key":"853_CR7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jaad.2016.07.001","volume":"75","author":"R Bahar","year":"2016","unstructured":"Bahar R, Zhou P, Liu Y, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol. 2016;75:1126\u201333.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"853_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1503\/cmaj.1040708","volume":"172","author":"A Haider","year":"2005","unstructured":"Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ. 2005;172(1):69\u201375.","journal-title":"CMAJ."},{"key":"853_CR9","unstructured":"International Hyperhidrosis Society. Primary focal axillary hyperhidrosis. 2018. http:\/\/www.sweathelp.org\/. Accessed 17 Sep 2019."},{"key":"853_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13555-016-0148-z","volume":"7","author":"DA Grabell","year":"2017","unstructured":"Grabell DA, Hebert AA. Current and emerging medical therapies for primary hyperhidrosis. Dermatol Ther (Heidelb). 2017;7:25\u201336.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"853_CR11","unstructured":"Dermira Inc. Qbrexza (glycopyrronium cloth): US prescribing information. 2018. http:\/\/pi.dermira.com\/. Accessed 17 Sep 2019."},{"key":"853_CR12","doi-asserted-by":"crossref","unstructured":"Dermira Inc. Qbrexza: frequently asked questions. 2019. http:\/\/www.qbrexza.com\/. Accessed 17 Sep 2019.","DOI":"10.12968\/indn.2019.7.17"},{"issue":"1","key":"853_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","volume":"80","author":"DA Glaser","year":"2019","unstructured":"Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128\u201338.e2.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"853_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40257-019-00446-6","volume":"20","author":"DA Glaser","year":"2019","unstructured":"Glaser DA, Hebert AA, Nast A, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593\u2013604.","journal-title":"Am J Clin Dermatol."},{"issue":"1","key":"853_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40257-018-0395-0","volume":"20","author":"DM Pariser","year":"2019","unstructured":"Pariser DM, Hebert AA, Drew J, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135\u201345.","journal-title":"Am J Clin Dermatol."},{"issue":"1","key":"853_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/pde.13723","volume":"36","author":"AA Hebert","year":"2019","unstructured":"Hebert AA, Glaser DA, Green L, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatr Dermatol. 2019;36(1):89\u201399.","journal-title":"Pediatr Dermatol."},{"issue":"Suppl 2","key":"853_CR17","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.25251\/skin.2.supp.68","volume":"2","author":"AA Hebert","year":"2018","unstructured":"Hebert AA, Glaser DA, Green L, et al. Short- and long-term efficacy and safety of topical glycopyrronium cloth for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analyses from the phase 3 studies [poster no. S68]. Skin. 2018;2(Suppl 2):S68.","journal-title":"Skin."},{"key":"853_CR18","unstructured":"Glaser DA, Green L, Drew J, et al. Glycopyrronium cloth improves axillary hyperhidrosis across a broad spectrum of patients: post hoc analyses of the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials in patient subpopulations [abstract no. 8599]. In: 77th Annual Meeting of the American Academy of Dermatology. 2019."},{"issue":"3","key":"853_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jama.2019.8589","volume":"322","author":"R Micieli","year":"2019","unstructured":"Micieli R, Micieli JA. Dilated pupil in a patient with hyperhidrosis. JAMA. 2019;322(3):264\u20135.","journal-title":"JAMA."},{"key":"853_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2019.04.009","author":"A Pashaei-Marandi","year":"2019","unstructured":"Pashaei-Marandi A, Assam JH, Arnold A, et al. Reversible anisocoria due to inadvertent ocular exposure to topical anticholinergic treatment for primary axillary hyperhidrosis. Can J Ophthalmol. 2019. https:\/\/doi.org\/10.1016\/j.jcjo.2019.04.009.","journal-title":"Can J Ophthalmol."},{"key":"853_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s41687-019-0148-8","volume":"3","author":"LM Nelson","year":"2019","unstructured":"Nelson LM, DiBenedetti D, Pariser DM, et al. Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity. J Patient Rep Outcomes. 2019;3:59.","journal-title":"J Patient Rep Outcomes"},{"issue":"Suppl 10-a","key":"853_CR22","first-page":"S79","volume":"24","author":"K Gillard","year":"2018","unstructured":"Gillard K, Moradi A, Bloudek L. Budget impact analysis of glycopyrronium cloth for the treatment of primary axillary hyperhidrosis [abstract no. L14]. J Manag Care Spec Pharm. 2018;24(Suppl 10-a):S79.","journal-title":"J Manag Care Spec Pharm."}],"updated-by":[{"DOI":"10.1007\/s40261-019-00878-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00853-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-019-00853-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00853-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T18:13:24Z","timestamp":1627668804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-019-00853-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00853-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"30 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-019-00878-2","URL":"https:\/\/doi.org\/10.1007\/s40261-019-00878-2","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y N. Lamb is an employee of Adis International Ltd.\/Springer Nature, is responsible for the article content and declares no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}